The latest paper from our #ProstateCancer lab at @VHIO is now online #OpenAccess at @Nature_NPJ! (online ahead of final print version) It all started with the question: how does ATM-loss prostate cancer react to PARPi pressure? https://t.co/SDjsLlVcik

💊 #Investigación | El Simposio @sogug1 acogerá la presentación de los resultados del Proyecto Princis, un estudio con 84 hospitales sobre el uso real de fármacos financiados en cáncer genitourinario @aranglezalba @AEMPSGOB https://t.co/A3J5ScrmUB

Terrific manuscript from the superteam of @scocmem @b_szabados led by none other than @tompowles1 @BartsECMC. Indeed the whole article is rife with useful tables & figures but I am particularly fond of Table 1 which offers an excellent summary/perspective on FGFR3 directed tx.

Phase II 🇨🇳 (Eur Urol): neoadjuvant disitamab vedotin + gemcitabine for cisplatin-ineligible HER2 2+/3+ MIBC (n=26) 🎯pCR 59% (13/22) in RC pts, 50% ITT; 👉with 4 cycles pCR 75% in RC (9/12), ⬆️69% ITT (9/13). Encouraging signal, needs RCT 💉🧬 @EUplatinum

Key components of antibody drug conjugates 👇resistance mechanisms & key questions 👉Brilliant talk by @DrShariat on development of ADCs in #BladderCancer 👇@SanRaffaeleMI #GURetreat25 Milan, @urotoday @OncoAlert @AndreaNecchi @BladderCancerUS

Congratulations to @autumngagnonn on her publication demonstrating in pts treated with defined course ADT+abi that early d/c of LHRH-A allowed ongoing castrate T with abi mono but earlier and more reliable T recovery after stopping. @DanaFarber_GU

Bladder Preservation After Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality @emanuele_crupi @AndreaNecchi @IBCG_BladderCA Access @EurUrolFocus article here: https://t.co/XiVNwSkO9p #bladdercancer #bladderpreservation

Understanding end-of-life cancer biology. https://t.co/lDLJWWXdTE @Nature @NatureMedicine @NaturePortfolio #CancerResearch #PallOnc #CancerCare @Aiims1742

Incredible representation for chRCC at #IKCSNA25 including a phenomenal oral abstract presented by Sahil D. Doshi, MD summarizing the largest multi-institutional analysis to date on outcomes of metastatic chromophobe RCC with and without sarcomatoid features!

Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. https://t.co/0vqWHuJ9tm

@neerajaiims #EOC25 #AbuDhabi fantastic overview of #mCRPC #PrecisionMedicine @nsayeghmd

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent #ProstateCancer (LUNAR) https://t.co/keVtn8PoFO The phase II LUNAR trial (NCT05496959) evaluated whether adding neoadjuvant PSMA-targeted radioligand therapy

🧬 #Oncología | El estudio Aurea-SOGUG muestra resultados prometedores con atezolizumab + cisplatino fraccionado en pacientes frágiles con carcinoma urotelial metastásico  👉 https://t.co/DHtIZ7n3YP #CáncerDeVejiga #Investigación #CarcinomaUrotelial #Inmunoterapia

💊 Estudio #SOGUG-CABOMAYOR: cabozantinib como 1ª línea en pacientes mayores frágiles con #cáncerrenal avanzado mantiene actividad y toxicidad manejable. Un paso para ofrecer un esquema de tratamiento validado en población geriátrica ➡️ https://t.co/G1cUXI2VKc #GUOncology

🎓 ¡Soci@s de @sogug1! ¿Sin patrocinador? Aún puedes solicitar una BECA 🎯 🗓️ Plazo hasta el 28/10 a las 12h 📩 Escribe a 👉 eventos@sogug.es Toda la información en: https://t.co/P6dvwGoq33 #SOGUG #OncologíaGU #Oncología #FormaciónMédica @aranglezalba @imanolex

ALBAN, POTOMAC & CREST #ESMO25 (atezolizumab/sasalimab/in MIBC) @Annals_Oncology show a lot variability. It no easy to conclude exactly which NMIBC patients benefit from ICI therapy. There is over treatment and it’s not without toxicity @JoshMeeks

I guess we will never have prospective trials head to head to see if a non-selective ADC is better than a targeted agent against FGFR3 in metastatic urothelial cancer. This is why real-wrold data are key. Congrats to the UNITE team @AmandaNizamMD @OncoAlert Efficacy of

The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System

AMPLITUDE trial of niraparib abi just published - 1st confirmation of efficacy with PARPi in HRR-mutant mHSPC, with notable benefit in the BRCA subgroup.

ROME study @NatureMedicine randomized targeted therapy vs standard of care after molecular analysis (tissue/blood) in pretreated cancer patients across tumors. ⬆️ORR (17.5% vs 10%) & ⬆️PFS HR=0.66, but no OS (HR 0.92). OS feels important despite crossover ~45% . Congrats 🥳